Albany Molecular Research Inc. (NASDAQ:AMRI)’s share price rose 4.9% during mid-day trading on Wednesday . The stock traded as high as $14.46 and last traded at $14.39, with a volume of 115,179 shares traded. The stock had previously closed at $13.72.

Separately, Morgan Stanley reaffirmed a “buy” rating on shares of Albany Molecular Research in a research note on Sunday, May 8th.

The firm’s market cap is $499.62 million. The stock has a 50-day moving average of $14.03 and a 200 day moving average of $14.87.

Albany Molecular Research (NASDAQ:AMRI) last posted its earnings results on Tuesday, May 10th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by $0.14. The firm had revenue of $102.80 million for the quarter, compared to analyst estimates of $107.20 million. Equities analysts expect that Albany Molecular Research Inc. will post $1.05 earnings per share for the current fiscal year.

In other news, SVP Steven R. Hagen sold 2,361 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were sold at an average price of $12.77, for a total value of $30,149.97. Following the sale, the senior vice president now owns 37,564 shares of the company’s stock, valued at approximately $479,692.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Kevin Oconnor sold 5,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $14.41, for a total transaction of $72,050.00. Following the completion of the sale, the director now directly owns 52,955 shares in the company, valued at approximately $763,081.55. The disclosure for this sale can be found here.

Several large investors have recently bought and sold shares of the company. Mutual of America Capital Management LLC raised its stake in Albany Molecular Research by 5.8% in the fourth quarter. Mutual of America Capital Management LLC now owns 158,399 shares of the company’s stock valued at $3,144,000 after buying an additional 8,689 shares during the last quarter. Philadelphia Trust Co. increased its position in shares of Albany Molecular Research by 10.9% in the fourth quarter. Philadelphia Trust Co. now owns 153,475 shares of the company’s stock valued at $3,056,000 after buying an additional 15,025 shares during the period. Finally, Bank of Montreal Can increased its position in shares of Albany Molecular Research by 5.8% in the fourth quarter. Bank of Montreal Can now owns 878,664 shares of the company’s stock valued at $17,442,000 after buying an additional 48,436 shares during the period.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.